Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Clin |
RCV001759446 | SCV001994840 | benign | Mitochondrial disease | 2021-05-06 | reviewed by expert panel | curation | The c.3483-41 A>C variant in POLG is present in population databases at the following frequencies: 1000 genomes at 1.7%; gnomad at 1.4% with 246 homozygotes; ExAC 1.3% with 104 homozygotes (BA1; observed > 1% frequency and BS2). In summary, there is sufficient evidence to characterize this variant as benign for primary mitochondrial disease inherited in a autosomal recessive manner. ntDNA Mitochondrial ACMG-AMP Criteria for POLG applied: BA1, BS2 |
Wong Mito Lab, |
RCV000758551 | SCV000887283 | benign | Progressive sclerosing poliodystrophy | 2018-10-01 | criteria provided, single submitter | clinical testing | The NM_002693.2:c.3483-41A>C (NP_002684.1:p.=) [GRCH38: NC_000015.10:g.89317577T>G] variant in POLG gene is interpretated to be a Benign based on ACMG guidelines (PMID: 25741868). This variant meets the following evidence codes reported in the ACMG-guideline. BA1:Minor allele frequency is too high for the Mitochondrial DNA depletion syndrome 4A (Alpers type). BP4:Computational evidence/predictors indicate no impact on the POLG structure, function, or protein-protein interaction. Based on the evidence criteria codes applied, the variant is suggested to be Benign. |
Gene |
RCV001712745 | SCV001944609 | benign | not provided | 2019-07-25 | criteria provided, single submitter | clinical testing | |
Breakthrough Genomics, |
RCV001712745 | SCV005294868 | benign | not provided | criteria provided, single submitter | not provided |